Applications of Polymers as Pharmaceutical Excipients in Solid Oral Dosage Forms

Medicinal Research Reviews

Volumn 37, Issue 1, 2017, Pages 52-97

  Debotton, Nir ^a   Dahan, Arik ^b  

^a SHENKAR COLLEGE OF ENGINEERING AND DESIGN   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

biopharmaceutics; excipient; oral dosage form; oral drug delivery; Pharmacokinetics; polymer

Indexed keywords

ACID; AZO COMPOUND; DILUENT; DISINTEGRATING AGENT; EXCIPIENT; MUCOADHESIVE POLYMER; POLYMER; POLYMER BINDER; POLYMERIC SUPERDISINTEGRANT; POLYSACCHARIDE; THIOLATED MUCOADHESIVE POLYMER; UNCLASSIFIED DRUG; DRUG DOSAGE FORM;

ADHESION; BIODEGRADABILITY; BIODEGRADATION; COLON; DISPERSION; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG RELEASE; ENTERIC COATED TABLET; ENZYMATICALLY COLONIC COATING; FILM COATING; HUMAN; HYDROPHILICITY; MATRIX TABLET; MUCOADHESION; MULTIMATRIX DELIVERY SYSTEM; ORAL DRUG ADMINISTRATION; OSMOTIC POTENTIAL; PH; POLYMERIZATION; REVIEW; SOLID; CHEMISTRY;

ADMINISTRATION, ORAL; DOSAGE FORMS; DRUG DELIVERY SYSTEMS; EXCIPIENTS; HUMANS; POLYMERS;

EID: 84982965051     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.21403     Document Type: Review

References (154)

1. Convention USP. USP35 NF30, 2012: U. S. Pharmacopoeia National Formulary Rockville: United States Pharmacopeial; 2011. 5089 p.
2. FDA. Guidance for Industry Nonclinical Studies for the Safety Evaluation of Pharmaceutical Excipients. May 2005 ed. U.S. Food and Drug Administration, Rockville, Maryland; 2005. p 1–9.
3. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L. Membrane transporters in drug development. Nat Rev Drug Discov 2010;9(3):215–236.
4. Wu CY, Benet LZ. Predicting drug disposition via application of BCS: Transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 2005;22(1):11–23.
5. Custodio JM, Wu C-Y, Benet LZ. Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. Adv Drug Deliv Rev 2008;60(6):717–733.
6. Miller JM, Beig A, Carr RA, Spence JK, Dahan A. A win-win solution in oral delivery of lipophilic drugs: Supersaturation via amorphous solid dispersions increases apparent solubility without sacrifice of intestinal membrane permeability. Mol Pharm 2012;9(7):2009–2016.
7. Miller JM, Dahan A, Gupta D, Varghese S, Amidon GL. Enabling the intestinal absorption of highly polar antiviral agents: Ion-pair facilitated membrane permeation of zanamivir heptyl ester and guanidino oseltamivir. Mol Pharm 2010;7(4):1223–1234.
8. Wilde L, Bock M, Wolf M, Glockl G, Garbacz G, Weitschies W. Development of pressure-sensitive dosage forms with a core liquefying at body temperature. Eur J Pharm Biopharm 2014;86(3):507–513.
9. Lachman L. Physical and chemical stability testing of tablet dosage forms. J Pharm Sci 1965;54(10):1519–1526.
10. Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995;12(3):413–420.
11. Dahan A, Lennernäs H, Amidon GL. The fraction dose absorbed, in humans, and high jejunal human permeability relationship. Mol Pharm 2012;9(6):1847–1851.
12. Beig A, Miller JM, Dahan A. The interaction of nifedipine with selected cyclodextrins and the subsequent solubility–permeability trade-off. Eur J Pharm Biopharm 2013;85(3, Part B):1293–1299.
13. Dahan A, Miller J. The solubility–permeability interplay and its implications in formulation design and development for poorly soluble drugs. AAPS J 2012;14(2):244–251.
14. Tanaka N, Imai K, Okimoto K, Ueda S, Tokunaga Y, Ohike A, Ibuki R, Higaki K, Kimura T. Development of novel sustained-release system, disintegration-controlled matrix tablet (DCMT) with solid dispersion granules of nilvadipine. J Control Release 2005;108(2-3):386–395.
15. Kaunisto E, Tajarobi F, Abrahmsen-Alami S, Larsson A, Nilsson B, Axelsson A. Mechanistic modelling of drug release from a polymer matrix using magnetic resonance microimaging. Eur J Pharm Sci 2013;48(4-5):698–708.
16. Oh DH, Park YJ, Kang JH, Yong CS, Choi HG. Physicochemical characterization and in vivo evaluation of flurbiprofen-loaded solid dispersion without crystalline change. Drug Deliv 2011;18(1):46–53.
17. Widanapathirana L, Tale S, Reineke TM. Dissolution and solubility enhancement of the highly lipophilic drug phenytoin via interaction with poly(N-isopropylacrylamide-co-vinylpyrrolidone) excipients. Mol Pharm 2015;12(7):2537–2543.
18. Curatolo W, Liu P, Johnson BA, Hausberger A, Quan E, Vendola T, Vatsaraj N, Foulds G, Vincent J, Chandra R. Effects of food on a gastrically degraded drug: Azithromycin fast-dissolving gelatin capsules and HPMC capsules. Pharm Res 2011;28(7):1531–1539.
19. Emara LH, Taha NF, Badr RM, Mursi NM. Development of an osmotic pump system for controlled delivery of diclofenac sodium. Drug Discov Ther 2012;6(5):269–277.
20. Emara LH, Taha NF, El-Ashmawy AA, Raslan HM, Mursi NM. Controlled porosity osmotic pump system for the delivery of diclofenac sodium: In-vitro and in-vivo evaluation. Pharm Dev Technol 2014;19(6):681–691.
21. Niwa K, Takaya T, Morimoto T, Takada K. Preparation and evaluation of a time-controlled release capsule made of ethylcellulose for colon delivery of drugs. J Drug Target 1995;3(2):83–89.
22. Takaya T, Niwa K, Muraoka M, Ogita I, Nagai N, Yano R, Kimura G, Yoshikawa Y, Yoshikawa H, Takada K. Importance of dissolution process on systemic availability of drugs delivered by colon delivery system. J Control Release 1998;50(1-3):111–122.
23. Wang B, Liu Z, Li D, Yang S, Hu J, Chen H, Sheng L, Li Y. Application of physiologically based pharmacokinetic modeling in the prediction of pharmacokinetics of bicyclol controlled-release formulation in human. Eur J Pharm Sci 2015;77:265–272.
24. Hunter AC, Elsom J, Wibroe PP, Moghimi SM. Polymeric particulate technologies for oral drug delivery and targeting: A pathophysiological perspective. Nanomedicine 2012;8(Suppl 1):S5–S20.
25. Pathak K, Raghuvanshi S. Oral bioavailability: Issues and solutions via nanoformulations. Clin Pharmacokinet 2015;54(4):325–357.
26. Troy DB, Remington JP, Beringer P. Remington: The Science and Practice of Pharmacy, 20th Edition. Philadelphia: Lippincott Williams & Wilkins; 2006. 1050 p.
27. Lieberman H, Lachman L, Schwartz JB. Pharmaceutical Dosage Forms: Tablets, Vol. 1. 2nd Edition. New York: Marcel Dekker 1989. 592 p.
28. Cerea M, Zheng W, Young CR, McGinity JW. A novel powder coating process for attaining taste masking and moisture protective films applied to tablets. Int J Pharm 2004;279(1-2):127–139.
29. Gryczke A, Schminke S, Maniruzzaman M, Beck J, Douroumis D. Development and evaluation of orally disintegrating tablets (ODTs) containing Ibuprofen granules prepared by hot melt extrusion. Colloids Surf B Biointerfaces 2011;86(2):275–284.
30. Kim JI, Cho SM, Cui JH, Cao QR, Oh E, Lee BJ. In vitro and in vivo correlation of disintegration and bitter taste masking using orally disintegrating tablet containing ion exchange resin-drug complex. Int J Pharm 2013;455(1-2):31–39.
31. Obara S, Maruyama N, Nishiyama Y, Kokubo H. Dry coating: An innovative enteric coating method using a cellulose derivative. Eur J Pharm Biopharm 1999;47(1):51–59.
32. Pearnchob N, Siepmann J, Bodmeier R. Pharmaceutical applications of shellac: Moisture-protective and taste-masking coatings and extended-release matrix tablets. Drug Dev Ind Pharm 2003;29(8):925–938.
33. Srinarong P, Faber JH, Visser MR, Hinrichs WL, Frijlink HW. Strongly enhanced dissolution rate of fenofibrate solid dispersion tablets by incorporation of superdisintegrants. Eur J Pharm Biopharm 2009;73(1):154–161.
34. Thoma K, Bechtold K. Influence of aqueous coatings on the stability of enteric coated pellets and tablets. Eur J Pharm Biopharm 1999;47(1):39–50.
35. Vercruysse J, Delaet U, Van Assche I, Cappuyns P, Arata F, Caporicci G, De Beer T, Remon JP, Vervaet C. Stability and repeatability of a continuous twin screw granulation and drying system. Eur J Pharm Biopharm 2013;85(3 Pt B):1031–1038.
36. Wardrop J, Law D, Qiu Y, Engh K, Faitsch L, Ling C. Influence of solid phase and formulation processing on stability of Abbott-232 tablet formulations. J Pharm Sci 2006;95(11):2380–2392.
37. Cole ET, Cade D, Benameur H. Challenges and opportunities in the encapsulation of liquid and semi-solid formulations into capsules for oral administration. Adv Drug Deliv Rev 2008;60(6):747–756.
38. Ford JL, Rubinstein MH, McCaul F, Hogan JE, Edgar PJ. Importance of drug type, tablet shape and added diluents on drug release kinetics from hydroxypropylmethylcellulose matrix tablets. Int J Pharm 1987;40(3):223–234.
39. Velasco MV, Ford JL, Rowe P, Rajabi-Siahboomi AR. Influence of drug:hydroxypropylmethylcellulose ratio, drug and polymer particle size and compression force on the release of diclofenac sodium from HPMC tablets. J Control Release 1999;57(1):75–85.
40. Vueba ML, Batista de Carvalho LA, Veiga F, Sousa JJ, Pina ME. Role of cellulose ether polymers on ibuprofen release from matrix tablets. Drug Dev Ind Pharm 2005;31(7):653–665.
41. Johnson JR, Wang LH, Gordon MS, Chowhan ZT. Effect of formulation solubility and hygroscopicity on disintegrant efficiency in tablets prepared by wet granulation, in terms of dissolution. J Pharm Sci 1991;80(5):469–471.
42. Augsburger LL, Hoag SW. Pharmaceutical Dosage Forms—Tablets. 3rd Edition. Taylor & Francis; New York: Informa Healthcare 2008.
43. Bley O, Siepmann J, Bodmeier R. Characterization of moisture-protective polymer coatings using differential scanning calorimetry and dynamic vapor sorption. J Pharm Sci 2009;98(2):651–664.
44. Rowe RC, Sheskey PJ, Quinn ME, Association AP. Handbook of Pharmaceutical Excipients, 6th edition. London: Pharmaceutical Press; 2009. 888 p.
45. Tan BM, Loh ZH, Soh JL, Liew CV, Heng PW. Distribution of a viscous binder during high shear granulation–sensitivity to the method of delivery and its impact on product properties. Int J Pharm 2014;460(1-2):255–263.
46. Joneja SK, Harcum WW, Skinner GW, Barnum PE, Guo J-H. Investigating the fundamental effects of binders on pharmaceutical tablet performance. Drug Dev Ind Pharm 1999;25(10):1129–1135.
47. Nadadivya P, Ramakrishna R, Sridhar G, Bhanushashank R. Effect of various binding agents on tablet hardness and release rate profiles of diclofenac sodium tablets. Int J Res Pharm Sci 2012;3(1):12–16.
48. Alderborn G, Ahlneck C. Moisture adsorption and tabletting. III. Effect on tablet strenght-post compaction storage time profiles. Int J Pharm 1991;73(3):249–258.
49. Kiekens F, Zelko R, Remon JP. Effect of the storage conditions on the tensile strength of tablets in relation to the enthalpy relaxation of the binder. Pharm Res 2000;17(4):490–493.
50. Al-Gousous J, Langguth P. Oral solid dosage form dsintegration testing—the forgotten test. J Pharm Sci 2015;104(9):2664–2675.
51. Iwao Y, Tanaka S, Uchimoto T, Noguchi S, Itai S. An easy-to-use approach for determining the disintegration ability of disintegrants by analysis of available surface area. Int J Pharm 2013;448(1):1–8.
52. Lowenthal W. Mechanism of action of tablet disintegrants: Correlation of tablet mean pore diameter and porosity. J Pharm Sci 1972;61(2):303–304.
53. Lowenthal W, Burruss RA. Mechanism of action of starch as a tablet disintegrant IV: Effect of medicaments and disintegrants on mean pore diameter and porosity. J Pharm Sci 1971;60(9):1325–1332.
54. Shotton E, Leonard GS. Effect of intragranular and extragranular disintegrating agents on particle size of disintegrated tablets. J Pharm Sci 1976;65(8):1170–1174.
55. Bele MH, Derle DV. Effect of sorbed water on disintegrant performance of four brands of Polacrilin Potassium NF. AAPS PharmSciTech 2012;13(1):24–34.
56. Azad M, Afolabi A, Bhakay A, Leonardi J, Davé R, Bilgili E. Enhanced physical stabilization of fenofibrate nanosuspensions via wet co-milling with a superdisintegrant and an adsorbing polymer. Eur J Pharm Biopharm 2015;94:372–385.
57. Gordon MS, Rudraraju VS, Dani K, Chowhan ZT. Effect of the mode of super disintegrant incorporation on dissolution in wet granulated tablets. J Pharm Sci 1993;82(2):220–226.
58. Digenis GA, Gold TB, Shah VP. Cross-linking of gelatin capsules and its relevance to their in vitro-in vivo performance. J Pharm Sci 1994;83(7):915–921.
59. Marques MR. Enzymes in the dissolution testing of gelatin capsules. AAPS PharmSciTech 2014;15(6):1410–1416.
60. Shah KB, Augsburger LL, Marshall K. Multiple tamping effects on drug dissolution from capsules filled on a dosing-disk type automatic capsule filling machine. J Pharm Sci 1987;76(8):639–645.
61. Cole ET, Scott RA, Cade D, Connor AL, Wilding IR. In vitro and in vivo pharmacoscintigraphic evaluation of ibuprofen hypromellose and gelatin capsules. Pharm Res 2004;21(5):793–798.
62. Cole ET, Scott RA, Connor AL, Wilding IR, Petereit HU, Schminke C, Beckert T, Cade D. Enteric coated HPMC capsules designed to achieve intestinal targeting. Int J Pharm 2002;231(1):83–95.
63. European Medicines Agency. ICH Topic Q 6 A. Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances, (European Medicines Agency website) EMEA; London; 2000. p. 1–32.
64. FDA. CDER Data Standards Manual (C-DRG-00201 Version 008). U.S. Food and Drug Administration, Rockville, Maryland; 2006.
65. Folkman J, Long DM. The use of silicone rubber as a carrier for prolonged drug therapy. J Surg Res 1964;4:139–142.
66. Borgquist P, Korner A, Piculell L, Larsson A, Axelsson A. A model for the drug release from a polymer matrix tablet–effects of swelling and dissolution. J Control Release 2006;113(3):216–225.
67. Theeuwes F. Elementary osmotic pump. J Pharm Sci 1975;64(12):1987–1991.
68. Guo M, Lv Z, Li Y, Pan X, Yang C, Li Q, Wang X, LAN P, Zhao L, Liu Y. BEIJING UNION PHARMACEUTICAL FACTORY, assignee. Double-layer osmotic pump controlled release tablet of bicyclol and preparation method thereof patent EP2471521 A1. 2012.
69. Banerjee A, Verma PR, Gore S. Controlled porosity solubility modulated osmotic pump tablets of gliclazide. AAPS PharmSciTech 2015;16(3):554–568.
70. Boyapally H, Nukala RK, Douroumis D. Development and release mechanism of diltiazem HCl prolonged release matrix tablets. Drug Deliv 2009;16(2):67–74.
71. Siepmann J, Streubel A, Peppas NA. Understanding and predicting drug delivery from hydrophilic matrix tablets using the “sequential layer” model. Pharm Res 2002;19(3):306–314.
72. Li L, Wang L, Shao Y, Tian Y, Li C, Li Y, Mao S. Elucidation of release characteristics of highly soluble drug trimetazidine hydrochloride from chitosan-carrageenan matrix tablets. J Pharm Sci 2013;102(8):2644–2654.
73. Jenquin MR, Sarabia RE, Liebowitz SM, McGinity JW. Relationship of film properties to drug release from monolithic films containing adjuvants. J Pharm Sci 1992;81(10):983–989.
74. Varshosaz J, Faghihian H, Rastgoo K. Preparation and characterization of metoprolol controlled-release solid dispersions. Drug Deliv 2006;13(4):295–302.
75. Pietrzak K, Isreb A, Alhnan MA. A flexible-dose dispenser for immediate and extended release 3D printed tablets. Eur J Pharm Biopharm 2015;(96):380–387.
76. Morita Y, Tsushima Y, Yasui M, Termoz R, Ajioka J, Takayama K. Evaluation of the disintegration time of rapidly disintegrating tablets via a novel method utilizing a CCD camera. Chem Pharm Bull 2002;50(9):1181–1186.
77. Schiermeier S, Schmidt PC. Fast dispersible ibuprofen tablets. Eur J Pharm Sci 2002;15(3):295–305.
78. Morott JT, Pimparade M, Park JB, Worley CP, Majumdar S, Lian Z, Pinto E, Bi Y, Durig T, Repka MA. The effects of screw configuration and polymeric carriers on hot-melt extruded taste-masked formulations incorporated into orally disintegrating tablets. J Pharm Sci 2015;104(1):124–134.
79. Graham CC. Pharmaceutical Coating Technology. London: Taylor & Francis; 1995. p 489 p.
80. Mehta RY, Missaghi S, Tiwari SB, Rajabi-Siahboomi AR. Application of ethylcellulose coating to hydrophilic matrices: A strategy to modulate drug release profile and reduce drug release variability. AAPS PharmSciTech 2014;15(5):1049–1059.
81. Fairstein M, Swissa R, Dahan A. Regional-dependent intestinal Permeability and BCS classification: Elucidation of pH-related complexity in rats using pseudoephedrine. AAPS J 2013;15(2):589–597.
82. Zur M, Hanson AS, Dahan A. The complexity of intestinal permeability: Assigning the correct BCS classification through careful data interpretation. Eur J Pharm Sci 2014;30(61):11–17.
83. Koziolek M, Grimm M, Becker D, Iordanov V, Zou H, Shimizu J, Wanke C, Garbacz G, Weitschies W. Investigation of pH and temperature profiles in the GI tract of fasted human subjects using the intellicap® system. J Pharm Sci 2015;104(9):2855–2863.
84. Dahan A, Miller JM, Hilfinger JM, Yamashita S, Yu LX, Lennernäs H, Amidon GL. High-permeability criterion for BCS classification: Segmental/pH dependent permeability considerations. Mol Pharm 2010;7(5):1827–1834.
85. Dressman J, Berardi R, Dermentzoglou L, Russell T, Schmaltz S, Barnett J, Jarvenpaa K. Upper gastrointestinal (GI) pH in young, healthy men and women. Pharm Res 1990;7(7):756–761.
86. Evans DF, Pye G, Bramley R, Clark AG, Dyson TJ, Hardcastle JD. Measurement of gastrointestinal pH profiles in normal ambulant human subjects. Gut 1988;29(8):1035–1041.
87. Mudie DM, Amidon GL, Amidon GE. Physiological parameters for oral delivery and in vitro testing. Mol Pharm 2010;7(5):1388–1405.
88. Min DS, Um KA, Kim YS, Park PW; Sunkyong Industries Co., Ltd., assignee. Method for preparing enteric-coated oral drugs containing acid-unstable compounds patent. US5399700 A. 1995.
89. Walker J, Robinson J, Stewart J, Jacob S. Does enteric-coated aspirin result in a lower incidence of gastrointestinal complications compared to normal aspirin? Interact Cardiovasc Thorac Surg 2007;6(4):519–522.
90. Varum FJ, Merchant HA, Goyanes A, Assi P, Zboranova V, Basit AW. Accelerating the dissolution of enteric coatings in the upper small intestine: Evolution of a novel pH 5.6 bicarbonate buffer system to assess drug release. Int J Pharm 2014;468(1-2):172–177.
91. Leopold CS, Eikeler D. Basic coating polymers for the colon-specific drug delivery in inflammatory bowel disease. Drug Dev Ind Pharm 2000;26(12):1239–1246.
92. Dahan A, Amidon GL, Zimmermann EM. Drug targeting strategies for the treatment of inflammatory bowel disease: A mechanistic update. Expert Rev Clin Immunol 2010;6(4):543–550.
93. Dahan A, Zimmermann E, Ben-Shabat S. Modern prodrug design for targeted oral drug delivery. Molecules 2014;19(10):16489–16505.
94. Wolk O, Epstein S, Ioffe-Dahan V, Ben-Shabat S, Dahan A. New targeting strategies in drug therapy of inflammatory bowel disease: Mechanistic approaches and opportunities. Expert Opin Drug Deliv 2013;10(9):1275–1286.
95. Dahan A, Ben-Shabat S, Cohen N, Keinan S, Kurnikov I, Aponick A, Zimmermann E. Phospholipid-based prodrugs for drug targeting in inflammatory bowel disease: Computational optimization and in-vitro correlation. Curr Top Med Chem 2016;16: in press.
96. Ashford M, Fell JT, Attwood D, Sharma H, Woodhead PJ. An in vivo investigation into the suitability of pH dependent polymers for colonic targeting. Int J Pharm 1993;95(1–3):193–199.
97. Roediger WE, Lawson MJ, Kwok V, Grant AK, Pannall PR. Colonic bicarbonate output as a test of disease activity in ulcerative colitis. J Clin Pathol 1984;37(6):704–707.
98. Hardy JG, Healey JN, Reynolds JR. Evaluation of an enteric-coated delayed-release 5-aminosalicylic acid tablet in patients with inflammatory bowel disease. Aliment Pharmacol Ther 1987;1(4):273–280.
99. Khan MZ, Prebeg Z, Kurjakovic N. A pH-dependent colon targeted oral drug delivery system using methacrylic acid copolymers. I. Manipulation of drug release using Eudragit L100-55 and Eudragit S100 combinations. J Control Release 1999;58(2):215–222.
100. Travis SP, Danese S, Kupcinskas L, Alexeeva O, D'Haens G, Gibson PR, Moro L, Jones R, Ballard ED, Masure J, Rossini M, Sandborn WJ. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: Results from the randomised CORE II study. Gut 2014;63(3):433–441.
101. Hiorth M, Skoien T, Sande SA. Immersion coating of pellet cores consisting of chitosan and calcium intended for colon drug delivery. Eur J Pharm Biopharm 2010;75(2):245–253.
102. Ji CM, Xu HN, Wu W. Guar gum as potential film coating material for colon-specific delivery of fluorouracil. J Biomater Appl 2009;23(4):311–329.
103. Karrout Y, Neut C, Siepmann F, Wils D, Ravaux P, Deremaux L, Flament MP, Dubreuil L, Lemdani M, Desreumaux P, Siepmann J. Enzymatically degraded Eurylon 6 HP-PG: Ethylcellulose film coatings for colon targeting in inflammatory bowel disease patients. J Pharm Pharmacol 2010;62(12):1676–1684.
104. Karrout Y, Neut C, Wils D, Siepmann F, Deremaux L, Desreumaux P, Siepmann J. Characterization of ethylcellulose: Starch-based film coatings for colon targeting. Drug Dev Ind Pharm 2009;35(10):1190–1200.
105. Karrout Y, Neut C, Wils D, Siepmann F, Deremaux L, Desreumaux P, Siepmann J. Novel polymeric film coatings for colon targeting: How to adjust desired membrane properties. Int J Pharm 2009;371(1-2):64–70.
106. Rabiskova M, Bautzova T, Gajdziok J, Dvorackova K, Lamprecht A, Pellequer Y, Spilkova J. Coated chitosan pellets containing rutin intended for the treatment of inflammatory bowel disease: In vitro characteristics and in vivo evaluation. Int J Pharm 2012;422(1-2):151–159.
107. Wei H, Qing D, De-Ying C, Bai X, Fanli F. Pectin/Ethylcellulose as film coatings for colon-specific drug delivery: Preparation and in vitro evaluation using 5-fluorouracil pellets. PDA J Pharm Sci Technol 2007;61(2):121–130.
108. Bragger JL, Lloyd AW, Soozandehfar SH, Bloomfield SF, Marriott C, Martin GP. Investigations into the azo reducing activity of a common colonic microorganism. Int J Pharm 1997;157(1):61–71.
109. Dahan A, Amidon GL. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol 2009;297(2):G371–G377.
110. Saffran M, Kumar GS, Savariar C, Burnham JC, Williams F, Neckers DC. A new approach to the oral administration of insulin and other peptide drugs. Science 1986;233(4768):1081–1084.
111. Van den Mooter G, Samyn C, Kinget R. In vivo evaluation of a colon-specific drug delivery system: An absorption study of theophylline from capsules coated with azo polymers in rats. Pharm Res 1995;12(2):244–247.
112. Yamaoka T, Makita Y, Sasatani H, Kim SI, Kimura Y. Linear type azo-containing polyurethane as drug-coating material for colon-specific delivery: Its properties, degradation behavior, and utilization for drug formulation. J Control Release 2000;66(2-3):187–197.
113. Van den Mooter G, Samyn C, Kinget R. The relation between swelling properties and enzymatic degradation of azo polymers designed for colon-specific drug delivery. Pharm Res 1994;11(12):1737–1741.
114. Rogers J, Henry MM, Misiewicz JJ. Increased segmental activity and intraluminal pressures in the sigmoid colon of patients with the irritable bowel syndrome. Gut 1989;30(5):634–641.
115. Barakat NS, Al-Suwayeh SA, Taha EI, Bakry Yassin AE. A new pressure-controlled colon delivery capsule for chronotherapeutic treatment of nocturnal asthma. J Drug Target 2011;19(5):365–372.
116. Muraoka M, Hu Z, Shimokawa T, Sekino S, Kurogoshi R, Kuboi Y, Yoshikawa Y, Takada K. Evaluation of intestinal pressure-controlled colon delivery capsule containing caffeine as a model drug in human volunteers. J Control Release 1998;52(1-2):119–129.
117. Hassan EE, Gallo JM. A simple rheological method for the in vitro assessment of mucin-polymer bioadhesive bond strength. Pharm Res 1990;7(5):491–495.
118. Schipper NG, Olsson S, Hoogstraate JA, deBoer AG, Varum KM, Artursson P. Chitosans as absorption enhancers for poorly absorbable drugs 2: Mechanism of absorption enhancement. Pharm Res 1997;14(7):923–929.
119. Gupta V, Hwang BH, Lee J, Anselmo AC, Doshi N, Mitragotri S. Mucoadhesive intestinal devices for oral delivery of salmon calcitonin. J Control Release 2013;172(3):753–762.
120. Desai KG, Mallery SR, Holpuch AS, Schwendeman SP. Development and in vitro-in vivo evaluation of fenretinide-loaded oral mucoadhesive patches for site-specific chemoprevention of oral cancer. Pharm Res 2011;28(10):2599–2609.
121. Lueβen HL, Bohner V, Pérard D, Langguth P, Verhoef JC, de Boer AG, Merkle HP, Junginger HE. Mucoadhesive polymers in peroral peptide drug delivery. V. Effect of poly(acrylates) on the enzymatic degradation of peptide drugs by intestinal brush border membrane vesicles. Int J Pharm 1996;141(1–2):39–52.
122. Puratchikody A, Prasanth VV, Mathew ST, Kumar BA. Mucoadhesive patches of Salbutamol sulphate for unidirectional buccal drug delivery: Development and evaluation. Curr Drug Deliv 2011;8(4):416–425.
123. Kast CE, Guggi D, Langoth N, Bernkop-Schnurch A. Development and in vivo evaluation of an oral delivery system for low molecular weight heparin based on thiolated polycarbophil. Pharm Res 2003;20(6):931–936.
124. Bernkop-Schnurch A, Hornof M, Zoidl T. Thiolated polymers–thiomers: Synthesis and in vitro evaluation of chitosan-2-iminothiolane conjugates. Int J Pharm 2003;260(2):229–237.
125. Hauptstein S, Dezorzi S, Prufert F, Matuszczak B, Bernkop-Schnurch A. Synthesis and in vitro characterization of a novel S-protected thiolated alginate. Carbohydr Polym 2015;124:1–7.
126. Partenhauser A, Laffleur F, Rohrer J, Bernkop-Schnürch A. Thiolated silicone oil: Synthesis, gelling and mucoadhesive properties. Acta Biomater 2015;16:169–177.
127. Dahan A, Miller J, Amidon G. Prediction of solubility and permeability class membership: Provisional BCS classification of the world's top oral drugs. AAPS J 2009;11(4):740–746.
128. Lobenberg R, Amidon GL. Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur J Pharm Biopharm 2000;50(1):3–12.
129. Martinez MN, Amidon GL. A mechanistic approach to understanding the factors affecting drug absorption: A review of fundamentals. J Clin Pharmacol 2002;42(6):620–643.
130. Beig A, Agbaria R, Dahan A. Oral delivery of lipophilic drugs: The tradeoff between solubility increase and permeability decrease when using cyclodextrin-based formulations. PLoS One 2013;8(7):e68237.
131. Beig A, Agbaria R, Dahan A. The use of captisol (SBE7-β-CD) in oral solubility-enabling formulations: Comparison to HPβCD and the solubility–permeability interplay. Eur J Pharm Sci 2015;77:73–78.
132. Beig A, Miller JM, Dahan A. Accounting for the solubility–permeability interplay in oral formulation development for poor water solubility drugs: The effect of PEG-400 on carbamazepine absorption. Eur J Pharm Biopharm 2012;81(2):386–391.
133. Miller JM, Beig A, Carr RA, Webster GK, Dahan A. The solubility–permeability interplay when using cosolvents for solubilization: Revising the way we use solubility-enabling formulations. Mol Pharm 2012;9(3):581–590.
134. Miller JM, Beig A, Krieg BJ, Carr RA, Borchardt TB, Amidon GE, Amidon GL, Dahan A. The solubility-permeability Interplay: Mechanistic modeling and predictive application of the impact of micellar solubilization on intestinal permeation. Mol Pharm 2011;8(5):1848–1856.
135. Miller JM, Dahan A. Predicting the solubility–permeability interplay when using cyclodextrins in solubility-enabling formulations: Model validation. Int J Pharm 2012;430(1–2):388–391.
136. Beig A, Miller JM, Lindley D, Carr RA, Zocharski P, Agbaria R, Dahan A. Head-to-head comparison of different solubility-enabling formulations of etoposide and their consequent solubility-permeability interplay. J Pharm Sci 2015;104(9):2941–2947.
137. Dahan A, Beig A, Ioffe-Dahan V, Agbaria R, Miller JM. The twofold advantage of the amorphous form as an oral drug delivery practice for lipophilic compounds: Increased apparent solubility and drug flux through the intestinal membrane. AAPS J 2013;15(2):347–353.
138. Dahan A, Beig A, Lindley D, Miller JM. The solubility–permeability interplay and oral drug formulation design: Two heads are better than one. Adv Drug Deliv Rev 2016;101:99–107.
139. Almeida e Sousa L, Reutzel-Edens SM, Stephenson GA, Taylor LS. Assessment of the amorphous “solubility” of a group of diverse drugs using new experimental and theoretical approaches. Mol Pharm 2015;12(2):484–495.
140. Park K. Drug release mechanisms from amorphous solid dispersions. J Control Release 2015;211:171.
141. Purohit HS, Taylor LS. Phase separation kinetics in amorphous solid dispersions upon exposure to water. Mol Pharm 2015;12(5):1623–1635.
142. Sun DD, Lee PI. Probing the mechanisms of drug release from amorphous solid dispersions in medium-soluble and medium-insoluble carriers. J Control Release 2015;211:85–93.
143. Chella N, Daravath B, Kumar D, Tadikonda RR. Formulation and pharmacokinetic evaluation of polymeric dispersions containing valsartan. Eur J Drug Metab Pharmacokinet 2015;1–10.
144. Duong TV, Van Humbeeck J, Van den Mooter G. Crystallization kinetics of indomethacin/polyethylene glycol dispersions containing high drug loadings. Mol Pharm 2015;12(7):2493–2504.
145. FDA. Inactive Ingredient Search for Approved Drug Products. U.S. Food and Drug Administration: Center for Drug Evaluation and Research, Rockville, Maryland; 2016.
146. Huang WX, Desai M, Tang Q, Yang R, Vivilecchia RV, Joshi Y. Elimination of metformin-croscarmellose sodium interaction by competition. Int J Pharm 2006;311(1-2):33–39.
147. Quinteros DA, Rigo VR, Kairuz AF, Olivera ME, Manzo RH, Allemandi DA. Interaction between a cationic polymethacrylate (Eudragit E100) and anionic drugs. Eur J Pharm Sci 2008;33(1):72–79.
148. Osei-Yeboah F, Zhang M, Feng Y, Sun CC. A formulation strategy for solving the overgranulation problem in high shear wet granulation. J Pharm Sci 2014;103(8):2434–2440.
149. Good DJ, Hartley R, Mathias N, Crison J, Tirucherai G, Timmins P, Hussain M, Haddadin R, Koo O, Nikfar F, Fung NK. Mitigation of adverse clinical events of a narrow target therapeutic index compound through modified release formulation design: An in vitro, in vivo, in silico, and clinical pharmacokinetic analysis. Mol Pharm 2015;12(12):4434–4444.
150. Nicholson SJ, Timmins P, Dockens RC, Connor A, Croop R, Ferrie P, Zeng J, Dennis AB, Wilding I. Development of oral extended release formulations of 6-hydroxybuspirone. Biopharm Drug Dispos 2012;33(9):522–535.
151. Pawar VK, Meher JG, Singh Y, Chaurasia M, Surendar Reddy B, Chourasia MK. Targeting of gastrointestinal tract for amended delivery of protein/peptide therapeutics: Strategies and industrial perspectives. J Control Release 2014;196:168–183.
152. Liu H, Yang XG, Nie SF, Wei LL, Zhou LL, Liu H, Tang R, Pan WS. Chitosan-based controlled porosity osmotic pump for colon-specific delivery system: Screening of formulation variables and in vitro investigation. Int J Pharm 2007;332(1-2):115–124.
153. Singh D, Pathak K. Hydrogen bond replacement–unearthing a novel molecular mechanism of surface solid dispersion for enhanced solubility of a drug for veterinary use. Int J Pharm 2013;441(1-2):99-110.
154. Urbanetz NA. Stabilization of solid dispersions of nimodipine and polyethylene glycol 2000. Eur J Pharm Sci 2006;28(1-2):67–76.